BACKGROUND: Despite optimized medical therapy, severe idiopathic pulmonary arterial hypertension (IPAH) is a devastating disease with a poor outcome. Autoantibodies have been detected in IPAH that can contribute to worsening of the disease. OBJECTIVES: The objective of this prospective, open-label, single-arm, multicenter trial was to evaluate the safety and efficacy of immunoadsorption (IA) as an add-on to optimized medical treatment for patients with IPAH. METHODS: A total of 10 IPAH patients received IA over 5 days. Their clinical parameters, including hemodynamics measured by right heart catheter, were assessed at baseline and after 3 and 6 months. The primary endpoint was the change in pulmonary vascular resistance (PVR). Secondary endpoints included the change in 6-min walking distance, quality of life, safety, and plasma levels of IgG and autoantibodies. RESULTS: The evaluation of the 10 IPAH patients (75% female; 51 ± 12 years; 166 ± 10 cm; WHO functional class III; 53% on combination therapy) revealed that IA was a safe procedure that efficiently removed IgG and autoantibodies from the circulation. After 3 months, the mean PVR improved significantly by 13.2% (p = 0.03) and the cardiac index improved by 13.1%, but no significant changes were found in 6-min walking distance. The quality of life physical functioning subscale score significantly improved after 6 months. The serious adverse events in 3 patients were possibly related to IA and included pneumonia, temporary disturbance in attention, and thrombocytopenia. CONCLUSIONS: IA as an add-on to targeted medical treatment for IPAH is a safe procedure with beneficial effects on hemodynamics, especially in patients with high levels of autoantibodies. Larger-scale controlled studies are needed to assess its efficacy in IPAH and to identify responders.
BACKGROUND: Despite optimized medical therapy, severe idiopathic pulmonary arterial hypertension (IPAH) is a devastating disease with a poor outcome. Autoantibodies have been detected in IPAH that can contribute to worsening of the disease. OBJECTIVES: The objective of this prospective, open-label, single-arm, multicenter trial was to evaluate the safety and efficacy of immunoadsorption (IA) as an add-on to optimized medical treatment for patients with IPAH. METHODS: A total of 10 IPAH patients received IA over 5 days. Their clinical parameters, including hemodynamics measured by right heart catheter, were assessed at baseline and after 3 and 6 months. The primary endpoint was the change in pulmonary vascular resistance (PVR). Secondary endpoints included the change in 6-min walking distance, quality of life, safety, and plasma levels of IgG and autoantibodies. RESULTS: The evaluation of the 10 IPAH patients (75% female; 51 ± 12 years; 166 ± 10 cm; WHO functional class III; 53% on combination therapy) revealed that IA was a safe procedure that efficiently removed IgG and autoantibodies from the circulation. After 3 months, the mean PVR improved significantly by 13.2% (p = 0.03) and the cardiac index improved by 13.1%, but no significant changes were found in 6-min walking distance. The quality of life physical functioning subscale score significantly improved after 6 months. The serious adverse events in 3 patients were possibly related to IA and included pneumonia, temporary disturbance in attention, and thrombocytopenia. CONCLUSIONS: IA as an add-on to targeted medical treatment for IPAH is a safe procedure with beneficial effects on hemodynamics, especially in patients with high levels of autoantibodies. Larger-scale controlled studies are needed to assess its efficacy in IPAH and to identify responders.
Authors: Kelley L Colvin; Patrick J Cripe; D Dunbar Ivy; Kurt R Stenmark; Michael E Yeager Journal: Am J Respir Crit Care Med Date: 2013-11-01 Impact factor: 21.405
Authors: Laura C Price; S John Wort; Frédéric Perros; Peter Dorfmüller; Alice Huertas; David Montani; Sylvia Cohen-Kaminsky; Marc Humbert Journal: Chest Date: 2012-01 Impact factor: 9.410
Authors: A Staudt; F Schäper; V Stangl; A Plagemann; M Böhm; K Merkel; G Wallukat; K D Wernecke; K Stangl; G Baumann; S B Felix Journal: Circulation Date: 2001-06-05 Impact factor: 29.690
Authors: J Hoffmann; J Yin; M Kukucka; N Yin; I Saarikko; A Sterner-Kock; H Fujii; H Leong-Poi; H Kuppe; R T Schermuly; W M Kuebler Journal: Eur Respir J Date: 2010-12-09 Impact factor: 16.671
Authors: T Gazdic; I Malek; L Pagacova; A Slavcev; L Voska; M Hegarova; L Hoskova; M Kubanek; J Pirk Journal: Transplant Proc Date: 2016-10 Impact factor: 1.066
Authors: Alexander Staudt; Yvonne Staudt; Astrid Hummel; Klaus Empen; Marcus Dörr; Christiane Trimpert; Katrin Birkenmeier; Uwe Kühl; Michel Noutsias; Dirk Russ; Stephan B Felix Journal: Ther Apher Dial Date: 2006-02 Impact factor: 1.762